Search This Blog

Friday, November 1, 2019

Warren releases Medicare for All plan: ‘No tax hike on middle class’

Sen. Elizabeth Warren (D-Mass.) on Friday released a new plan on how she would pay for her Medicare for All proposal that would not raise taxes on the middle class, responding to pressure from other Democrats in the presidential race.
The plan is a shift from Warren’s progressive rival in the Democratic race for the White House, Sen. Bernie Sanders (I-Vt.), who has said tax hikes on the middle class will be necessary to help pay for Medicare for All.
Warren and Sanders have both argued that Medicare for All will lead to lower healthcare spending overall.
Warren said that her Medicare for All plan would allow every American to have full heath and long-term care coverage. She said her plan would cost an additional $20.5 trillion in new federal spending, a lower estimate than the $34 trillion in new spending the Urban Institute had said would be needed,. .
To pay for the plan, Warren wrote in a post on Medium that she would redirect some funds from states to help fund Medicare.
“After incorporating the $6 trillion we will redirect from states to help fund Medicare, the experts conclude that total new federal spending required to enact Medicare for All will be $20.5 trillion,” she wrote.
The proposal comes as Warren as polls show her in the driver’s seat ahead of the Iowa caucuses, and as opponents have clamored for her to explain how she would pay for the proposal.

Neovasc to file U.S. application for Reducer this quarter

After meeting with the FDA and “weighing all available options” Neovasc (NVCN) has decided to file a U.S. application for Neovasc Reducer by year-end.
It believes that data from the COSIRA trial, REDUCER-I European Post-Market study and multiple independent studies published in peer-reviewed journals should be sufficient to support a PMA application. It also intends to request an advisory committee meeting.
Reducer is a stent-like device used to treat refractory angina (chest pain caused by inadequate blood flow to the heart).

Price tag for Warren’s universal healthcare: $20.5T

Presidential candidate Senator Elizabeth Warren (D-MA) has finally released the projected cost of her plan for universal healthcare, called “Medicare for All,” a whopping $20.5T over 10 years.
She says funding will come from tax increases on businesses and billionaires, sparing the middle class from any tax hikes.
Fellow candidate Bernie Sanders (I-VT) is also endorsing Medicare for All while other Democratic hopefuls are espousing less-ambitious plans based on the continuation of Obamacare.
Selected tickers: THWBMEGRXIXJXLVKMEDVHTIBBIHIIYHFHLC

Rhythm Pharmaceuticals EPS beats by $0.03

Rhythm Pharmaceuticals (NASDAQ:RYTM): Q3 GAAP EPS of -$1.04 beats by $0.03.
Cash and equivalents of $71.68M

Google to acquire Fitbit for $7.35/share

Fitbit (NYSE:FITwill be acquired by Google (GOOG,GOOGL) in a deal that values FIT at a fully diluted equity value of approximately $2.1B.
The transaction is expected to close in 2020, subject to stockholder and regulatory approvals.
FIT shares were halted ahead of the announcement.
The $7.35 per share price is just shy of a 20% premium to last night’s close, and about double the price FIT was trading at prior to the rumors of a buyout.

EyePoint Pharma up 8% premarket on Vizient agreement

EyePoint Pharmaceuticals (NASDAQ:EYPT) is up 8% premarket on modest volume in reaction to its three-year agreement with Vizient under which it will offer postoperative eye inflammation med DEXYCU (dexamethasone intraocular suspension 9%) to its membership at a discounted price.
Vizient, the integration of VHA, University HealthSystem and Novation, includes more than half of U.S. acute care providers and more than 20% of ambulatory care providers.

Baird softens view on Celgene ahead of hematology meet

Baird’s Brian Skorney has downgraded Celgene (NASDAQ:CELG) to Neutral with a $101 price target citing its 27% climb this year and the Bristol-Myers deal spread narrowing to $0.66.
He also does not see a valid reason to hold shares ahead of The American Society of Hematology (ASH) Annual Meeting in early December where “anything amiss” related to ozanimod, liso-cel or bb2121 could put the $9/share Contingent Value Right (CVR) at risk, adding that CAR-T therapy liso-cel is the riskiest of the three.
Shares are up a fraction premarket.